Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 COLEMAN PR - Endo International plc | colemancfoannouncementpr.htm |
| EX-10.1 - EXHIBIT 10.1 COLEMAN AGREEMENT - Endo International plc | ex101colemanemploymentagre.htm |
________________________________________________________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________________________________________________________________________
FORM 8-K/A
______________________________________________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): December 22, 2016
______________________________________________________________________________________________________
ENDO INTERNATIONAL PLC
(Exact Name of Registrant as Specified in Its Charter)
______________________________________________________________________________________________________
Ireland | 001-36326 | 68-0683755 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland | Not Applicable |
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code 011-353-1-268-2000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
This amendment updates the disclosure to Item 5.02 of the Current Report on Form 8-K filed by Endo International plc (“Endo”) on October 21, 2016.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 20, 2016, Endo announced that Blaise Coleman was appointed to serve as Interim Chief Financial Officer, effective November 22, 2016, while Endo conducted a search for a permanent Chief Financial Officer. On December 20, 2016, Endo announced that after a thorough assessment and search process, Endo appointed Mr. Coleman to permanently assume the role of Executive Vice President and Chief Financial Officer, effective December 19, 2016. A copy of Endo’s press release announcing Mr. Coleman’s appointment is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
In connection with Mr. Coleman’s appointment as Executive Vice President and Chief Financial Officer, Endo Health Solutions Inc. (the “Company”), an indirect, wholly-owned subsidiary of Endo, entered into an employment agreement with Mr. Coleman, dated as of December 22, 2016 (the “Employment Agreement”). The Employment Agreement has a term of three years ending on December 19, 2019, unless earlier terminated. Under the Employment Agreement, Mr. Coleman is entitled to an annual base salary of $525,000, and he is eligible to receive a target annual cash bonus of 55% of his base salary.
During the term of the Employment Agreement, Mr. Coleman is also eligible to receive equity-based compensation on an annual basis to be awarded in the sole discretion of the Compensation Committee of Endo’s Board of Directors (the “Committee”), which may be subject to the achievement of certain performance targets established by the Committee. Beginning with grants made in 2017, Mr. Coleman is eligible to receive equity-based compensation with a targeted grant date fair market value equal to 250% of his base salary, subject to any increase in the Committee’s sole discretion. Mr. Coleman is also entitled to receive benefits on the same basis as other senior executives.
The Employment Agreement also provides that in the event of a termination of Mr. Coleman’s employment by the Company without Cause or by Mr. Coleman for Good Reason (as these terms are defined in the Employment Agreement), Mr. Coleman will be entitled to the following benefits, subject to his execution of a release of claims: a prorated bonus for the year of termination (based on actual performance results), severance in an amount equal to two times the sum of his base salary and target bonus, and continued medical and life insurance benefits for two years following termination. Mr. Coleman may elect to reduce his severance payments to the extent these payments would constitute “excess parachute payments” under Sections 280G and 4999 of the Internal Revenue Code. Payments upon termination due to death or disability include a prorated bonus for the year of termination (based on actual performance results), continued medical and life insurance benefits for Mr. Coleman and/or his dependents for two years following such termination and, in the event of disability, 24 months of salary continuation offset by disability benefits. If, within 90 days following the expiration of the Employment Agreement, Mr. Coleman’s employment is terminated by the Company under circumstances that would not have constituted Cause or by Mr. Coleman under circumstances that would have constituted Good Reason, he will receive a prorated bonus for the year of termination (based on actual performance results), and the termination will be treated as a termination without Cause or for Good Reason for purposes of any performance-based long-term incentive awards held by Mr. Coleman as of the date of such termination of employment.
The Employment Agreement also contains an 18-month non-solicitation covenant, a 12-month non-competition covenant, a non-disparagement covenant and a covenant providing for cooperation by Mr. Coleman in connection with any investigations and/or litigation.
The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by the full text of the Employment Agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) | Exhibits. |
Exhibit Number | Description |
10.1 | Executive Employment Agreement between Endo Health Solutions Inc. and Blaise Coleman, dated December 22, 2016. |
99.1 | Press Release of Endo International plc dated December 20, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ENDO INTERNATIONAL PLC | |
By: | /s/ Matthew J. Maletta |
Name: | Matthew J. Maletta |
Title: | Executive Vice President, |
Chief Legal Officer | |
Dated: December 22, 2016
INDEX TO EXHIBITS
Exhibit Number | Description |
10.1 | Executive Employment Agreement between Endo Health Solutions Inc. and Blaise Coleman, dated December 22, 2016. |
99.1 | Press Release of Endo International plc dated December 20, 2016. |